BioLife Solutions Inc. Common Stock (BLFS)

FairStock Score: 41/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I wear two hats: Buffett's search for durable earning power and Graham's insistence on a margin of safety. BioLife operates in a niche supplying biopreservation media and services to cell and gene therapy developers. Revenue is growing: fiscal Q2 2026, the quarter ended 2026-06-30, showed $28.5M revenue, up from $23.4M in fiscal Q2 2025. The latest quarter also reported $45.1M net income and $0.91 diluted EPS, a startling swing from fiscal Q2 2025's $15.8M loss. That single quarter is encouraging, but the annual record is not: FY2025 lost $4.6M, FY2024 lost $20.2M, and FY2023 lost $68.0M. FairStock's computed Lynch category is 'none' because the company has not earned a profit in each of the last four years. Financial position is lightly levered with D/E 0.04, Piotroski 6/9, and Altman Z 40.70, but trailing free cash flow is -$2.2M. At the 2026-10-07 close of $38.61 and $1.9B market cap, FairStock's P/E is 38.61, P/B 4.49, EV/EBITDA 293.30, and Graham Number $13.90—a -177.77% margin of safety. ROCE is only 0.26%. The product lineup in a regulated CGT supply chain may create stickiness, but the figures do not yet prove durable pricing power. Growth is real, but profitability and cash generation are unproven. I would need consistent earnings and a price closer to intrinsic value before seeing a Graham-style bargain.

In plain English: BioLife makes preservation materials and services used by companies developing cell and gene therapies. The business is growing sales and recently reported a large quarterly profit, but it has mostly lost money in recent years and its cash flow is slightly negative. At the recent close, the stock price looks expensive compared with the company's sales, profits, and accounting value, so the numbers do not show an obvious bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-07 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer